Search results for "FEV1"

showing 10 items of 132 documents

Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease

2008

SummaryBackgroundEpidemiologic studies have demonstrated that elderly patients with fixed airflow obstruction can be affected by asthma or chronic obstructive pulmonary disease (COPD).MethodsWe studied 49 consecutive elderly outpatients, presenting fixed airflow obstruction, by clinical history (smoking), pulmonary function tests, blood gas analysis, and induced sputum.ResultsThe age was not different in patients with COPD (n=28) and asthma (n=21) (70.2±3.9 years vs. 69.6±3.7 years), also the degree of fixed airflow obstruction was similar (FEV1: 58.3±1.5% vs. 59.0±1.4% of predicted). Patients with asthma had significantly more eosinophils in peripheral blood (0.43±0.05×10−3μL vs. 0.27±0.1×…

MalePulmonary and Respiratory MedicineVital capacitymedicine.medical_specialtySettore MED/09 - Medicina Internaasthma chronic obstructive pulmonary disease.NeutrophilsVital Capacitychronic obstructive pulmonary disease.GastroenterologyPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioElderlyDLCOForced Expiratory VolumeInternal medicinemedicineHumanselderly patients; fixed airflow obstruction; asthma; chronic obstructive pulmonary disease.AgedAsthmaCOPDEosinophil cationic proteinbusiness.industryChronic obstructive pulmonary diseasefixed airflow obstructionRespiratory diseaseSputumasthmamedicine.diseaseRespiratory Function Testselderly patientrespiratory tract diseasesSurgeryEosinophilsFemalebusinessRespiratory Medicine
researchProduct

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

2011

SummaryBackgroundIndacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the treatment of COPD.MethodsThis 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD. Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea index (TDI) and rescue medication use.ResultsOf 1123 patients randomised 92.1% completed. Mean ± SD age was 62.8 ± 8.78 years, p…

MalePulmonary and Respiratory Medicinemedicine.drug_classbeta2-agonistQuinolonesDrug Administration Schedulelaw.inventionFEV1/FVC ratioPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawBronchodilatorForced Expiratory VolumeClinical endpointmedicineCOPDHumansAlbuterolSalmeterolSalmeterol XinafoateIndacaterolCOPDDose-Response Relationship Drugbusiness.industryrespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsRespiratory Function TestsTreatment OutcomeAnesthesiaIndansIndacaterolFemaleSalmeterolOnce dailybusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct

Development of chronic hypoventilation in amyotrophic lateral sclerosis patients

2006

SummaryEarly prediction of respiratory muscle involvement and chronic hypoventilation (CH) in amyotrophic lateral sclerosis (ALS) patients can help to plan mechanical ventilatory aids and palliative care interventions well before respiratory failure occurs. To describe the natural history of the progressive pulmonary dysfunction leading to CH, and to identify potential parameters associated with its development in ALS, we prospectively followed 38 ALS patients up to 26 months, starting from their first presentation at our Clinic. At study entry, median FVC was 87% (interquartile range: 72–104%) and declined by 10% after 6 months (range: 2–49%), showing a very high inter-patient variability.…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPalliative caremedicine.medical_treatmentVital CapacityFEV1/FVC ratiodisease progressionPatient Education as TopicInterquartile rangeInternal medicinemedicineRespiratory muscleHumansamyotrophic lateral sclerosiProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyLungAgedProportional Hazards ModelsMechanical ventilationbusiness.industryAmyotrophic Lateral SclerosisPalliative CareAge FactorsHypoventilationMiddle Agedmedicine.diseaseRespiration ArtificialRespiratory MusclesFVCSurgeryRespiratory failureChronic DiseaseFemalebusinesschronic hypoventilationAppel ALS Rating ScaleRespiratory Medicine
researchProduct

Prevalence of Co-morbidities and severity of COPD

2014

Abstract We aimed at exploring whether the prevalence of co-morbidities of chronic obstructive pulmonary disease (COPD) increases with COPD severity. Analysis of medical records of outpatients with established diagnosis of COPD was retrospectively performed. The lower limit of normality (LLN) for FEV1/FVC was applied to establish the occurrence of airway obstruction in the elderly population. The prevalence of co-morbidities was calculated, and the proportion of patients with each co-morbidity along with GOLD stages was analysed by chi-square for trend. A total of 326 (M/F: 256/70) consecutive outpatients with COPD (stage GOLD I to IV), aging 71.8 ± 9.2 years, were included in the analysis.…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtysystemic effectsprevalenceComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness IndexCoronary artery diseasePulmonary Disease Chronic ObstructiveFEV1/FVC ratioco-morbiditieInternal medicineDiabetes mellitusEpidemiologymedicineHumansCOPDAgedRetrospective StudiesAged 80 and overCOPDbusiness.industryMiddle AgedAirway obstructionmedicine.diseaserespiratory tract diseasesHeart failurePhysical therapyFemaleepidemiologyUnderweightmedicine.symptombusiness
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Bulbar impairment score predicts noninvasive volume-cycled ventilation failure during an acute lower respiratory tract infection in ALS.

2015

Amyotrophic lateral sclerosis (ALS) patients can suffer episodes of lower respiratory tract infections (LRTI) leading to an acute respiratory failure (ARF) requiring noninvasive ventilation (NIV).To determine whether clinical or functional parameters can predict noninvasive management failure during LRTI causing ARF in ALS.A prospective study involving all ALS patients with ARF requiring NIV in a Respiratory Care Unit. NIV was provided with volume-cycled ventilators.63 ALS patients were included (APACHE II: 14.93±3.56, Norris bulbar subscore (NBS): 18.78±9.68, ALSFRS-R: 19.90±6.98, %FVC: 40.01±18.07%, MIC: 1.62±0.74L, PCF 2.51±1.15L/s, PImax -34.90±19.44cmH2O, PEmax 51.20±28.84cmH2O). In 73…

MaleSeverity of Illness Indexlaw.inventionFEV1/FVC ratiolawLower respiratory tract infectionOutcome Assessment Health CareMedicineHumansTreatment FailureMuscle SkeletalRespiratory Tract InfectionsAgedCOPDNoninvasive VentilationAPACHE IIRespiratory tract infectionsbusiness.industryAmyotrophic Lateral SclerosisRespiratory infectionMiddle Agedmedicine.diseasePrognosisIntensive care unitNeurologyRespiratory failureAnesthesiaAcute DiseaseFemaleNeurology (clinical)businessRespiratory InsufficiencyJournal of the neurological sciences
researchProduct

Global Lung Function Initiative 2012 reference values for spirometry in South Italian children

2017

Rationale Despite the widespread use of the Global Lung Function Initiative (GLI) 2012 reference values, there is still the need of testing their applicability in local areas. Objectives The aims of this study are to evaluate applicability of GLI reference equations in a large population-based sample of normal schoolchildren from Sicily, and to compare GLI and previous prediction equations in terms of spirometry test interpretation. Methods GLI equations were evaluated in 1243 normal schoolchildren, 49% males, aged 7–16 years, height 116–187 cm. Normality assumptions for the GLI z-scores (FEV1, FVC, FEV1/FVC) were tested, and bootstrap confidence intervals for the mean (0 expected) and …

MaleSpirometryPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyPulmonary functionAdolescentmedia_common.quotation_subjectVital CapacityStandard scoreWhite PeoplePulmonary function testing03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineReference ValuesForced Expiratory VolumemedicineHumans030212 general & internal medicineChildLungSicilyNormalityLung functionmedia_commonintegumentary systemmedicine.diagnostic_testbusiness.industryZ-scorerespiratory systemrespiratory tract diseasesAirway ObstructionItaly030228 respiratory systemSpirometryPaediatricReference valuesFemaleBootstrap confidence intervalbusinessReference equationcirculatory and respiratory physiologyDemography
researchProduct

Authors’ response

2012

Claudio Sorino,1,2 Salvatore Battaglia,1 Nicola Scichilone,1 Claudio Pedone,3 Raffaele Antonelli-Incalzi,3 Duane Sherrill,4 Vincenzo Bellia11Biomedical Department of Internal and Specialist Medicine, Section of Pulmonology, University of Palermo, Italy; 2Division of Pulmonology, S Anna Hospital, Como, Italy; 3Chair of Geriatrics, University Campus Bio-Medico, Roma, Italy; 4Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USABackground: The choice between lower limit of normal or fixed value of forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC) < 0.70 as the criterion for confirming airway obstruction is an open issue. In t…

MaleSpirometryVital capacitymedicine.medical_specialtyLetterCross-sectional studyVital CapacityInternational Journal of Chronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary function testingPulmonary Disease Chronic ObstructiveFEV1/FVC ratioForced Expiratory VolumeInternal medicinemedicineHumansAgedAged 80 and overlcsh:RC705-779COPDmedicine.diagnostic_testbusiness.industryGeneral MedicineHealthy elderlylcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaselung function test elderlyRespiratory Function TestsSurgeryrespiratory tract diseasesCross-Sectional StudiesItalyCardiologyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct

Pulmonary function and complications after laparoscopic cholecystectomy

1998

Objective: To investigate the impairment of pulmonary function and complications after laparoscopic compared with open cholecystectomy through an upper midline incision.Design: Prospective randomised trial.Setting: Teaching hospital, Spain.Subjects: 40 patients, 20 in each group.Interventions: Clinical examination, spirometry, arterial blood gas analysis, and chest radiographs before and after operation.Results: 48 hours postoperatively FVC and FEV had decreased to 56.7% and 53%, respectively, in the patients who had had open cholecystectomy, compared with 85.3% and 84.8% in the laparoscopic group (p < 0.0001). The mean (SD) postoperative percentage reductions in both Pa02 (86.1 (11.1) comp…

MaleSpirometrymedicine.medical_specialtyPartial Pressuremedicine.medical_treatmentVital CapacityPulmonary function testingFEV1/FVC ratioPostoperative ComplicationsForced Expiratory VolumemedicineHumansCholecystectomyProspective StudiesLaparoscopyLungmedicine.diagnostic_testbusiness.industryGallbladderRespiratory diseaseMiddle Agedmedicine.diseaseSurgeryOxygenmedicine.anatomical_structureCholecystectomy LaparoscopicFemaleSurgeryCholecystectomyComplicationbusinessEuropean Journal of Surgery
researchProduct

Associations of black carbon with lung function and airway inflammation in schoolchildren

2019

Background: Few studies have investigated the 24-hour respiratory health effects of personal black carbon (BC) and ultrafine particles (UFP) exposure in schoolchildren. The objective of this study was to investigate these associations with the lung function in children 10-years old with and without persistent respiratory symptoms. Methods: We conducted a cross-sectional study in 305 children (147 and 158 with and without persistent respiratory symptoms, respectively) from three European birth-cohorts: PARIS (France) and INMA Sabadell and Valencia (Spain). Personal 24-hour measurements of exposure concentrations to BC and UFP were performed by portable devices, before lung function testing. …

MaleVital capacity010504 meteorology & atmospheric sciencesVital Capacity010501 environmental sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract01 natural sciencesLung function parameters (FVC and FEV1)Forced Expiratory VolumeRespiratory systemChildLunglcsh:Environmental sciencesLung functionGeneral Environmental Sciencelcsh:GE1-350Airway inflammationrespiratory systemRespiratory Function Tests3. Good healthChild PreschoolBreathingFemaleFrancemedicine.medical_specialtyLung function parameters (FVC and FEV(1))SchoolchildrenNitric OxideFEV1/FVC ratioBlack carbonExposure concentrationsSootInternal medicineLung function parameters (FVC and FEV1medicineHumansFeNOBronchitis0105 earth and related environmental sciencesInflammation[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Health[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatricsbusiness.industryInfant NewbornInfantConfidence intervalrespiratory tract diseasesCross-Sectional Studies) FeNOUltrafine particlesSpainExhaled nitric oxideParticulate Matter[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct